Exscientia

GlaxoSmithKline and Exscientia enter strategic drug discovery collaboration

Thursday, July 6, 2017

Exscientia, an innovative company at the forefront of Artificial Intelligence (AI)-driven drug discovery, has entered into a strategic drug discovery collaboration with GlaxoSmithKline (GSK). During this collaboration, Exscientia will apply its AI-enabled platform and combine it with the expertise of GSK, in order to discover novel and selective small molecules for up to 10 disease-related targets, nominated by GSK across multiple therapeutic areas.

[Read More]